1. Academic Validation
  2. Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes

Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes

  • Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H659-H668. doi: 10.1152/ajpheart.00452.2017.
Yuichi Baba 1 2 Jason K Higa 1 Briana K Shimada 1 Kate M Horiuchi 1 Tomohiro Suhara 1 3 Motoi Kobayashi 1 Jonathan D Woo 1 Hiroko Aoyagi 1 Karra S Marh 1 Hiroaki Kitaoka 2 Takashi Matsui 1
Affiliations

Affiliations

  • 1 Center for Cardiovascular Research, Department of Anatomy, Biochemistry, and Physiology, John A. Burns School of Medicine, University of Hawai'i at Manoa , Honolulu, Hawaii.
  • 2 Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University , Kochi , Japan.
  • 3 Department of Anesthesiology, Keio University School of Medicine , Tokyo , Japan.
Abstract

Clinical studies have suggested that myocardial iron is a risk factor for left ventricular remodeling in patients after myocardial infarction. Ferroptosis has recently been reported as a mechanism of iron-dependent nonapoptotic cell death. However, Ferroptosis in the heart is not well understood. Mechanistic target of rapamycin (mTOR) protects the heart against pathological stimuli such as ischemia. To define the role of cardiac mTOR on cell survival in iron-mediated cell death, we examined cardiomyocyte (CM) cell viability under excess iron and Ferroptosis conditions. Adult mouse CMs were isolated from cardiac-specific mTOR transgenic mice, cardiac-specific mTOR knockout mice, or control mice. CMs were treated with ferric iron [Fe(III)]-citrate, erastin, a class 1 Ferroptosis inducer, or Ras-selective lethal 3 (RSL3), a class 2 Ferroptosis inducer. Live/dead cell viability assays revealed that Fe(III)-citrate, erastin, and RSL3 induced cell death. Cotreatment with ferrostatin-1, a Ferroptosis inhibitor, inhibited cell death in all conditions. mTOR overexpression suppressed Fe(III)-citrate, erastin, and RSL3-induced cell death, whereas mTOR deletion exaggerated cell death in these conditions. 2',7'-Dichlorodihydrofluorescein diacetate measurement of Reactive Oxygen Species (ROS) production showed that erastin-induced ROS production was significantly lower in mTOR transgenic versus control CMs. These findings suggest that Ferroptosis is a significant type of cell death in CMs and that mTOR plays an important role in protecting CMs against excess iron and Ferroptosis, at least in part, by regulating ROS production. Understanding the effects of mTOR in preventing iron-mediated cell death will provide a new therapy for patients with myocardial infarction. NEW & NOTEWORTHY Ferroptosis has recently been reported as a new form of iron-dependent nonapoptotic cell death. However, Ferroptosis in the heart is not well characterized. Using cultured adult mouse cardiomyocytes, we demonstrated that the mechanistic target of rapamycin plays an important role in protecting cardiomyocytes against excess iron and Ferroptosis.

Keywords

cardiomyocyte; ferroptosis; iron; mechanistic target of rapamycin.

Figures
Products